Slocum Gordon & Co LLP Sells 6,046 Shares of Kenvue Inc. (NYSE:KVUE)

Slocum Gordon & Co LLP trimmed its position in Kenvue Inc. (NYSE:KVUE) by 2.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 260,229 shares of the company’s stock after selling 6,046 shares during the period. Kenvue makes up approximately 4.6% of Slocum Gordon & Co LLP’s investment portfolio, making the stock its 7th largest holding. Slocum Gordon & Co LLP’s holdings in Kenvue were worth $5,556,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. State Street Corp boosted its position in Kenvue by 16.8% during the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after acquiring an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Kenvue by 8.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock worth $2,011,832,000 after purchasing an additional 7,115,374 shares in the last quarter. Holocene Advisors LP lifted its position in shares of Kenvue by 75.5% in the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock worth $321,194,000 after purchasing an additional 5,975,392 shares in the last quarter. M&G PLC boosted its holdings in Kenvue by 538.0% during the third quarter. M&G PLC now owns 4,341,172 shares of the company’s stock worth $99,847,000 after purchasing an additional 3,660,730 shares during the last quarter. Finally, FMR LLC grew its position in Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after purchasing an additional 3,075,019 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

NYSE:KVUE opened at $19.78 on Friday. The firm’s fifty day moving average price is $21.70 and its two-hundred day moving average price is $21.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market cap of $37.93 billion, a P/E ratio of 35.97, a P/E/G ratio of 2.05 and a beta of 1.45. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 4.15%. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Citigroup decreased their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. UBS Group dropped their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, January 16th. Finally, Barclays decreased their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.